MedPath

Ribavirin

RIBAVIRIN CAPSULES

Approved
Approval ID

b97cd49c-9e19-4a35-987c-06e62bb25b6b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 27, 2023

Manufacturers
FDA

Zydus Lifesciences Limited

DUNS: 918596198

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ribavirin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code65841-260
Application NumberANDA077224
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ribavirin
Product Specifications
Route of AdministrationORAL
Effective DateSeptember 27, 2023
FDA Product Classification

INGREDIENTS (8)

RIBAVIRINActive
Quantity: 200 mg in 1 1
Code: 49717AWG6K
Classification: ACTIB
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
CROSPOVIDONE (15 MPA.S AT 5%)Inactive
Code: 68401960MK
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
GELATINInactive
Code: 2G86QN327L
Classification: IACT
POVIDONEInactive
Code: FZ989GH94E
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ribavirin - FDA Drug Approval Details